Posteraro Brunella, De Angelis Giulia, Menchinelli Giulia, D'Inzeo Tiziana, Fiori Barbara, De Maio Flavio, Cortazzo Venere, Sanguinetti Maurizio, Spanu Teresa
Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.
Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
J Clin Med. 2021 Apr 17;10(8):1752. doi: 10.3390/jcm10081752.
The aim of this study was to characterize COVID-19 (SARS-CoV-2-infected) patients who develop bloodstream infection (BSI) and to assess risk factors associated with in-hospital mortality. We conducted a retrospective observational study of adult patients admitted for ≥48 h to a large Central Italy hospital for COVID-19 (1 March to 31 May 2020) who had or had not survived at discharge. We included only patients having blood cultures drawn or other inclusion criteria satisfied. Kaplan-Meier survival or Cox regression analyses were performed of 293 COVID-19 patients studied, 46 patients (15.7%) had a hospital-acquired clinically relevant BSI secondary to SARS-CoV-2 infection, accounting for 58 episodes (49 monomicrobial and 9 polymicrobial) in total. Twelve episodes (20.7%) occurred at day 3 of hospital admission. Sixty-nine species were isolated, including (32.8%), Enterobacterales (20.7%), (17.2%), (13.8%) and (10.3%). Of 69 isolates, 27 (39.1%) were multidrug-resistant organisms. Twelve (54.5%) of 22 patients for whom empirical antimicrobial therapy was inappropriate were infected by a multidrug-resistant organism. Of 46 patients, 26 (56.5%) survived and 20 (43.5%) died. Exploring variables for association with in-hospital mortality identified > 75-year age (HR 2.97, 95% CI 1.15-7.68, = 0.02), septic shock (HR 6.55, 95% CI 2.36-18.23, < 0.001) and BSI onset ≤ 3 days (HR 4.68, 95% CI 1.40-15.63, = 0.01) as risk factors independently associated with death. In our hospital, mortality among COVID-19 patients with BSI was high. While continued vigilance against these infections is essential, identification of risk factors for mortality may help to reduce fatal outcomes in patients with COVID-19.
本研究旨在对发生血流感染(BSI)的新型冠状病毒肺炎(COVID-19,即感染严重急性呼吸综合征冠状病毒2[SARS-CoV-2])患者进行特征描述,并评估与院内死亡相关的危险因素。我们对2020年3月1日至5月31日期间因COVID-19入住意大利中部一家大型医院≥48小时且出院时存活或未存活的成年患者进行了一项回顾性观察研究。我们仅纳入了进行过血培养或满足其他纳入标准的患者。对所研究的293例COVID-19患者进行了Kaplan-Meier生存分析或Cox回归分析,46例患者(15.7%)发生了继发于SARS-CoV-2感染的医院获得性临床相关BSI,总共出现了58次感染发作(49次单一微生物感染和9次多微生物感染)。12次发作(20.7%)发生在入院第3天。分离出69种菌株,包括[具体菌株1](32.8%)、肠杆菌科(20.7%)、[具体菌株2](17.2%)、[具体菌株3](13.8%)和[具体菌株4](10.3%)。在69株分离菌株中,27株(39.1%)为多重耐药菌。经验性抗菌治疗不恰当的22例患者中有12例(54.5%)感染了多重耐药菌。46例患者中,26例(56.5%)存活,20例(43.5%)死亡。探索与院内死亡相关的变量发现,年龄>75岁(HR 2.97,95%CI 1.15 - 7.68,P = 0.02)、感染性休克(HR 6.55,95%CI 2.36 - 18.23,P < 0.001)和BSI发病≤3天(HR 4.68,95%CI 1.40 - 15.63,P = 0.01)是与死亡独立相关的危险因素。在我们医院,发生BSI的COVID-19患者死亡率很高。虽然持续警惕这些感染至关重要,但识别死亡危险因素可能有助于降低COVID-19患者的致命结局。